Archer Aviation reports manufacturing ramp with six aircraft in production
Neurocrine Biosciences Inc (NASDAQ:NBIX), a $13.2 billion biopharmaceutical company trading at $133.50 per share, reported a significant insider transaction. Chief Scientific Officer Jude Onyia sold 59,819 shares of common stock on July 9, 2025, for approximately $7.8 million. According to InvestingPro analysis, the stock is currently trading at a high P/E multiple of 44.2x, while technical indicators suggest overbought conditions. The sales were executed at a weighted average price of $130.455, with individual transactions ranging from $130.00 to $131.45.
Onyia also exercised options to acquire 59,819 shares of Neurocrine Biosciences common stock at a price of $84.74 per share, for a total value of $5,069,062.
Following these transactions, Onyia directly owns 18,289 shares of Neurocrine Biosciences.
In other recent news, Neurocrine Biosciences has reported a series of significant developments. Goldman Sachs initiated coverage on Neurocrine with a Buy rating, citing a robust growth outlook and projecting a compound annual growth rate of 11% through 2030. UBS also raised its price target for Neurocrine to $174, noting positive indicators for the Crenessity drug launch, with expectations of continued robust patient additions. Additionally, Neurocrine released new data indicating that its drug Ingrezza significantly reduces cognitive and motor burdens in Huntington’s disease, with improvements noted in multiple symptoms. The company also presented findings showing enhanced quality of life for older adults with tardive dyskinesia using Ingrezza, highlighting its impact on health-related quality of life. In a strategic move, Neurocrine appointed Lewis (JO:LEWJ) Choi as Chief Information Officer, bringing extensive experience in IT and AI to bolster the company’s technology strategy. These updates reflect Neurocrine’s ongoing efforts to advance its clinical pipeline and enhance patient outcomes.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.